NASDAQ$ANGO
AngioDynamics Inc · Q1 2025 earnings
Q1 2025 earnings · · Investor relations
Briefing
AngioDynamics' first quarter of fiscal year 2025 results were announced, showing a slight revenue increase and progress in the Med Tech segment.
AngioDynamics reported a 1.1% increase in net sales compared to the prior-year quarter, with Med Tech net sales up by 8.7%. The company's GAAP loss per share was $0.31, and the adjusted loss per share was $0.11. The company submitted for FDA 510(k) clearance for Prostate Tissue indication for NanoKnife, received CE Mark Approval in Europe for the Auryon System, and initiated RECOVER-AV Clinical Trial in Europe for AlphaVac.
- Net sales increased by 1.1% compared to the prior-year quarter.
- Med Tech net sales increased by 8.7% year-over-year.
- Auryon and AlphaVac both delivered over 20% growth in the quarter.
- Submitted for FDA 510(k) clearance for Prostate Tissue indication for NanoKnife and Received CE Mark Approval in Europe for the Auryon System.
Headline financials
Revenue & EPS history
AngioDynamics · Revenue · Quarterly
$67.5M
Revenue by segment
AngioDynamics · $78.7M total across 2 segments · Q1 2024
- Med Device$52.8M-10.0%67.1%
- Med Tech$25.9M+13.4%32.9%
Forward guidance
For fiscal year 2025, AngioDynamics expects net sales in the range of $282 to $288 million, Med Tech net sales are expected to grow in the range of 10% to 12%, Med Device net sales are expected to grow in the range of 1% to 3%, gross margin to be approximately 52% to 53%, adjusted EBITDA loss of $2.5 million to $0, and adjusted loss per share in the range of $0.38 to $0.42.
Tailwinds
- Net sales to be in the range of $282 to $288 million, representing growth of between 4.2% – 6.4% over fiscal 2024 pro forma revenue of $270.7 million
- Med Tech net sales are expected to grow in the range of 10% to 12%
- Med Device net sales are expected to grow in the range of 1% to 3%
- Gross margin to be approximately 52% to 53%
- Adjusted EBITDA loss of $2.5 million to $0, compared to a pro forma adjusted EBITDA loss of $3.2 million in fiscal year 2024
Headwinds
- Adjusted loss per share in the range of $0.38 to $0.42, compared to pro forma adjusted loss per share of $0.45 in fiscal year 2024
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2025
-0.9%
Avg return
Earnings day
-2.4%
Avg return
5 days after
-3.7%
Avg return
30 days after
43%
28 / 65 earnings
Positive
+30.9%
Q2 2025
Best reaction
-26.2%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | +5.0% | -5.0% | — | |
| Q2 2026 | -13.5% | -25.5% | -24.0% | |
| Q1 2026 | +6.1% | -0.2% | +8.7% | |
| Q4 2025 | -10.2% | -9.8% | -9.3% | |
| Q3 2025 | +12.4% | -3.6% | -3.8% | |
| Q2 2025 | +30.9% | +32.6% | +17.4% | |
| Q1 2025 | -20.3% | -23.1% | -12.7% | |
| Q4 2024 | +24.8% | +21.1% | +25.8% | |
| Q3 2024 | +15.6% | +14.6% | +3.1% | |
| Q2 2024 | -17.7% | -20.1% | -23.5% | |
| Q1 2024 | -5.9% | -7.2% | -10.4% | |
| Q4 2023 | -2.5% | -3.8% | -16.1% | |
| Q3 2023 | -17.1% | -23.3% | -33.3% | |
| Q2 2023 | +11.5% | -1.0% | -1.3% | |
| Q1 2023 | -26.2% | -38.0% | -34.8% | |
| Q4 2022 | +4.4% | +6.4% | +21.3% | |
| Q3 2022 | +9.8% | +7.2% | -8.7% | |
| Q2 2022 | -15.5% | -15.5% | -25.8% | |
| Q1 2022 | +12.6% | +17.8% | +22.4% | |
| Q4 2021 | -7.0% | -8.6% | -3.9% | |
| Q3 2021 | +12.3% | +11.1% | +16.3% | |
| Q2 2021 | +14.7% | +14.2% | +24.7% | |
| Q1 2021 | +13.0% | +7.8% | -0.1% | |
| Q4 2020 | -11.5% | -11.8% | -12.7% | |
| Q3 2020 | -2.7% | +2.3% | -0.6% | |
| Q2 2020 | -9.2% | -11.3% | -17.0% | |
| Q1 2020 | -17.6% | -17.6% | -13.7% | |
| Q4 2019 | +6.8% | +6.2% | -4.8% | |
| Q3 2019 | -7.7% | -8.2% | -18.4% | |
| Q2 2019 | +6.7% | +6.7% | +8.6% | |
| Q1 2019 | -10.3% | -12.9% | -17.0% | |
| Q4 2018 | -9.2% | -7.8% | -5.4% | |
| Q3 2018 | +3.2% | +8.9% | +16.4% | |
| Q2 2018 | -1.8% | -0.1% | +5.1% | |
| Q1 2018 | -8.9% | -9.1% | -8.4% | |
| Q4 2017 | -5.9% | -3.5% | +5.1% | |
| Q3 2017 | +0.3% | -1.3% | -10.2% | |
| Q2 2017 | +1.7% | +3.2% | -2.5% | |
| Q1 2017 | -4.5% | -0.1% | -8.4% | |
| Q4 2016 | +10.6% | +14.1% | +8.4% | |
| Q3 2016 | -2.1% | — | — | |
| Q2 2016 | -8.7% | — | — | |
| Q1 2016 | -8.8% | — | — | |
| Q4 2015 | -2.3% | — | — | |
| Q3 2015 | -6.1% | — | — | |
| Q2 2015 | -0.9% | — | — | |
| Q1 2015 | +3.8% | — | — | |
| Q4 2014 | -5.0% | — | — | |
| Q3 2014 | -1.5% | — | — | |
| Q2 2014 | +6.1% | — | — | |
| Q1 2014 | +5.3% | — | — | |
| Q4 2013 | +1.3% | — | — | |
| Q3 2013 | -7.4% | — | — | |
| Q2 2013 | -2.4% | — | — | |
| Q1 2013 | -8.8% | — | — | |
| Q4 2010 | -0.9% | — | — | |
| Q4 2012 | +4.0% | — | — | |
| Q3 2011 | -1.3% | — | — | |
| Q3 2012 | -1.3% | — | — | |
| Q2 2012 | -5.7% | — | — | |
| Q2 2011 | -5.7% | — | — | |
| Q1 2011 | +3.5% | — | — | |
| Q4 2011 | +3.5% | — | — | |
| Q1 2012 | +3.5% | — | — | |
| Q3 2010 | +0.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro